Alvotech

Alvotech is a public limited liability company incorporated under Luxembourg law, focused on developing and manufacturing biosimilars for the global market. The company was founded in 2013 in Reykjavik, Iceland, with the mission to improve patient lives and the sustainability of the global healthcare ecosystem by broadening the availability and accessibility of biosimilars. Alvotech, previously known as Alvotech Lux Holdings S.A.S., was incorporated on August 23, 2021, as a simplified joint stock company. On June 15, 2022, its legal form changed from a simplified joint stock company (société par actions simplifiée) to a public limited liability company (société anonyme). The company owns no material assets other than its interests in Alvotech hf. and other subsidiaries, and does not operate any business directly. Its business is conducted through Alvotech hf., its direct, wholly-owned subsidiary, and its subsidiaries. The principal place of business is at 9, Rue de Bitbourg, L-1273 Luxembourg, Grand Duchy of Luxembourg. The mailing address of the group's principal executive office is Sæmundargata 15-19, 102 Reykjavík, Iceland. Capital expenditures for the years ended December 31, 2025, 2024, and 2023 amounted to $64.5 million, $53.7 million, and $33.2 million, respectively. These expenditures primarily consisted of property, plant and equipment, leasehold improvements, lab equipment, and computer equipment in Iceland.